Genomind Announces Two Major Appointments

Genomind Announces Two Major Appointments




Genomind Announces Two Major Appointments

Cynthia Kilroy Named Chief Strategy & Corporate Development Officer

Stephen R Saklad, PharmD, BCCP Joins the Company’s Scientific Advisory Board

KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–Today Genomind made two major leadership announcements. Cynthia Kilroy has joined the company as Chief Strategy & Corporate Development Officer and a member of the Genomind Executive Team. And Stephen R. Saklad, PharmD, BCCP, is joining the company’s Scientific Advisory Board (SAB).


Kilroy joins Genomind as the company’s genetic mental health solutions approach has achieved 100MM covered lives and significant momentum with providers, health plans, employer groups, pharmacies and patients. Kilroy’s remit will be to help accelerate growth partnerships with companies looking for advanced mental health solutions to improve patient outcomes and reduce costs of care.

She joins from Cognizant, where she held positions in their healthcare and health strategy groups. In addition to Cognizant, Kilroy has a wealth of senior level experience in the healthcare field, working with companies like Optum and Huron Consulting Group as well as her own firm, CCK Consulting, a healthcare consulting business providing strategic services to payers, providers, and start-ups alike.

“With Genomind accelerating its growth strategy, we believe Cynthia will be a great addition to our leadership team, helping us navigate the healthcare industry by providing strategic insight and effective business planning, which will help take Genomind to the next level,” said Shawn O’Brien, Chairman and CEO of Genomind. “We believe her talents will accelerate our mission of becoming The Mental Healthcare Company.”

Kilroy has an undergraduate BS from DeSales University in Computer Science and Marketing, along with a Fuqua School of Business, Duke University MBA in Healthcare Sector Management.

Stephen R Saklad PharmD, BCCP, has joined Genomind’s Scientific Advisory Board. Dr. Saklad is Clinical Professor of Pharmacotherapy, and Adjoint Professor at the University of Texas School of Medicine, and Director, Psychiatric Pharmacy Program at the San Antonio State Hospital, Texas Department of State Health Services. He is an expert clinical pharmacologist with special interest in psychopharmacology.

Dr. Saklad received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles and his Doctor of Pharmacy degree from the University of Southern California. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He has been the principal or co-investigator of Phase II, III, and IV studies of the efficacy, adverse effects and pharmacokinetics of agents for schizophrenia, mood disorders, depression, and other serious and persistent mental illness. He is the recipient of the UT Austin College of Pharmacy’s Teaching Award among other honors, and speaks frequently on these and related issues.

​“There are hundreds of drugs which have genetic biomarker information for providers in their label. Dr Saklad’s expertise in drug-drug and drug-gene interactions has been invaluable in the development of GenMedPro.,” said David S Krause MD, Chief Medical Officer of Genomind. “We look forward to his continued guidance as we expand the utility of our digital products.”

About Genomind

Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind® Professional PGx Express™, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients’ mental health treatment. The Company also recently launched GenMed✓ Pro™ – Genomind’s Smarter Precision Gene-Drug Interaction Software. This advanced medication management software was designed to help health professionals make safer prescribing decisions with speed and precision. In 2020 the company introduced the Genomind Mental Health Map™ – a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at www.genomind.com.

Contacts

Beth Balsam, Beth@X2PR.com